MX2010003269A - Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa. - Google Patents

Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.

Info

Publication number
MX2010003269A
MX2010003269A MX2010003269A MX2010003269A MX2010003269A MX 2010003269 A MX2010003269 A MX 2010003269A MX 2010003269 A MX2010003269 A MX 2010003269A MX 2010003269 A MX2010003269 A MX 2010003269A MX 2010003269 A MX2010003269 A MX 2010003269A
Authority
MX
Mexico
Prior art keywords
inhibition
treating cancer
aurora kinase
derivatives useful
pyrrolotriazine derivatives
Prior art date
Application number
MX2010003269A
Other languages
English (en)
Inventor
Steven Magnuson
Philip Wickens
Zhonghua Zhang
Ning Qi
Xin Ma
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40511812&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010003269(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of MX2010003269A publication Critical patent/MX2010003269A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Esta invención se relaciona a compuestos novedosos y procesos para su preparación, métodos para tratar enfermedades, particularmente Cáncer, que comprenden administrar los compuestos, y métodos para hacer composiciones farmacéuticas para el tratamiento o prevención de desordenes, particularmente Cáncer.
MX2010003269A 2007-09-25 2008-09-22 Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa. MX2010003269A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99514707P 2007-09-25 2007-09-25
PCT/US2008/077211 WO2009042543A1 (en) 2007-09-25 2008-09-22 Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase

Publications (1)

Publication Number Publication Date
MX2010003269A true MX2010003269A (es) 2010-08-02

Family

ID=40511812

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003269A MX2010003269A (es) 2007-09-25 2008-09-22 Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.

Country Status (13)

Country Link
US (1) US8138336B2 (es)
EP (1) EP2203060A4 (es)
JP (2) JP5678661B2 (es)
KR (1) KR20100075932A (es)
CN (1) CN101820762B (es)
AU (1) AU2008304620A1 (es)
CA (1) CA2700489A1 (es)
HK (1) HK1144392A1 (es)
IL (1) IL204692A0 (es)
MX (1) MX2010003269A (es)
TW (1) TW200930719A (es)
WO (1) WO2009042543A1 (es)
ZA (1) ZA201002438B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
BRPI0619146A2 (pt) * 2005-12-02 2011-09-13 Bayer Pharmaceuticals Corp derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
KR20100075932A (ko) * 2007-09-25 2010-07-05 바이엘 헬스케어, 엘엘씨 오로라 키나아제의 저해를 통하여 암을 치료하는데 유용한 피롤로트리아진 유도체
WO2010042684A1 (en) * 2008-10-08 2010-04-15 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CN102428086B (zh) * 2009-04-29 2014-08-20 内尔维阿诺医学科学有限公司 Cdk抑制剂的盐类
CN103929961A (zh) * 2011-06-20 2014-07-16 美国阿尔茨海默病研究所公司 化合物及其治疗应用
WO2013087647A1 (en) * 2011-12-15 2013-06-20 Bayer Intellectual Property Gmbh Substituted benzothienyl - pyrrolotriazines and uses thereof in the treatment cancer
WO2013124316A1 (en) 2012-02-23 2013-08-29 Bayer Intellectual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
EP4321513A2 (en) 2016-03-28 2024-02-14 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
DK1183033T3 (da) 1999-05-21 2006-06-06 Bristol Myers Squibb Co Pyrrolotriazininhibitorer af kinaser
JP2007514759A (ja) * 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
UY28931A1 (es) * 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7405213B2 (en) * 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP5193876B2 (ja) * 2005-12-02 2013-05-08 バイエル・ヘルスケア・エルエルシー オーロラキナーゼの阻害により癌を処置するために有用なピロロトリアジン誘導体
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
BRPI0619146A2 (pt) * 2005-12-02 2011-09-13 Bayer Pharmaceuticals Corp derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
KR20100075932A (ko) * 2007-09-25 2010-07-05 바이엘 헬스케어, 엘엘씨 오로라 키나아제의 저해를 통하여 암을 치료하는데 유용한 피롤로트리아진 유도체

Also Published As

Publication number Publication date
JP2014129418A (ja) 2014-07-10
IL204692A0 (es) 2010-11-30
HK1144392A1 (en) 2011-02-18
JP5797799B2 (ja) 2015-10-21
AU2008304620A1 (en) 2009-04-02
ZA201002438B (en) 2010-12-29
US8138336B2 (en) 2012-03-20
JP2010540455A (ja) 2010-12-24
JP5678661B2 (ja) 2015-03-04
CN101820762A (zh) 2010-09-01
CA2700489A1 (en) 2009-04-02
CN101820762B (zh) 2014-07-30
EP2203060A4 (en) 2010-12-22
TW200930719A (en) 2009-07-16
KR20100075932A (ko) 2010-07-05
US20100273800A1 (en) 2010-10-28
WO2009042543A1 (en) 2009-04-02
EP2203060A1 (en) 2010-07-07

Similar Documents

Publication Publication Date Title
WO2007064932A3 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200628473A (en) Novel heterocycles
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2006058868A8 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
ZA200703002B (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
TW200714604A (en) Substituted heterocycles and the uses thereof
WO2005111039A3 (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
WO2006034154A3 (en) Salts of 5-azacytidine
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
WO2010014253A3 (en) Ant4 inhibitor compounds and methods of use thereof
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
PL1732926T3 (pl) Inhibitory kinezyn motorycznych
WO2006108679A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer
TW200740808A (en) Inhibiteurs de proteines kinases